AMRN

Amarin Corporation plc ADR (AMRN) | Rumor.io

Amarin

AMRN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,702

Bullish sentiment (50-day avg)75%

Price to earnings ratio-7.34

Market capitalization279.9M

Earnings per share-1.2

Dividend yield (TTM)—

Revenue (annual)213.6M

Net income (annual)-38.8M

Social

What share of all stock conversation is about AMRN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% -0.01

Sep 5

Novartis' heart drug, pelacarsen, failed to meet its primary endpoint in a Phase III trial, reducing the risk of cardiovascular events.
Amarin's therapy, icosapent ethyl, has shown hard CV event reduction despite residual risk remaining after standard lipid therapy, and has emerging mechanistic data showing it can limit oxidation of Lp(a) without needing to lower the Lp(a) concentration itself.
Amarin's stock price is undervalued, with a market capitalization of around $2 billion, which is lower than its actual and realistic value, and its shareholders are deserving of some buyback or M&A attention.

Generated by AI

Sentiment

Of the messages about AMRN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% -50	75% +13.89	77.53% +2.09	89.68% +4.93
Bearish	50% new	25% -13.89	22.47% -2.09	10.32% -4.93

Bullish· Feb 25

AMRN has a strong cash position with $300M in cash and no debt, making it a relatively safe value play.
The company's decision to drop a less profitable business to focus on profits has improved its bottom line and is a positive development.
The current share price of $13.71 is undervalued and has the potential to reach $200/share, with some analysts predicting a buyout in the near future.

Bearish· Jun 4

The SCOTUS decision could potentially lead to increased US drug prices as generic drugmakers may be more likely to make and sell their lower-cost drugs.
Amarin's limited product portfolio and lack of a diversified business may make it less valuable and less attractive to potential buyers.
The company's ongoing legal issues, including the remanded court case, may continue to weigh on its stock price and make it harder for Amarin to generate shareholder value.

Generated by AI

Topics

Of the messages about AMRN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	62.5%	87.5%	55.63%
Controversies	0%	0%	3.13%	23.65%
Analysts	0%	0%	0%	3.98%
Macro	0%	37.5%	9.38%	4.22%
Earnings	0%	0%	0%	6.25%
Technical Analysis	0%	0%	0%	6.27%

Earnings· May 3

Amarin Corporation plc ($AMRN) reported Q1 2023 earnings, beating EPS expectations by 167% and revenue expectations by 6%.
The company's gross margin on net product revenue was 55%, down from 76% a year ago, primarily due to a decrease in net selling price.
Amarin's adjusted EPS loss of $0.02 beat the consensus of a loss of $0.03, and revenue of $85.98M beat the consensus of $81.23M.

Analysts· May 12

Goldman Sachs analyst Paul Choi downgraded Amarin Corp from Neutral to Sell, lowering the price target from $6 to $5.
The downgrade was attributed to the company's Q1 results showing revenue decline, and pressure from generics on the ongoing Vascepa launch in the U.S.
Amarin shares dropped 5% after the downgrade, with some analysts expressing skepticism about the validity of the downgrade and suggesting it may be a ploy to get the stock as low as possible for a rebound.

Announcements· Jun 24

Amarin Corporation plc (AMRN) has entered into an exclusive license and supply agreement with Recordati to commercialize VAZKEPA in 59 European countries, providing $25M upfront and up to $150M in sales milestones.
The deal is expected to yield approximately $70M in cost savings over the next 12 months and strengthen Amarin's financial position, potentially making the company cash flow positive.
The partnership allows Amarin to streamline its global operations, reducing costs and increasing the potential for profitability, with Recordati responsible for commercialization of VAZKEPA in Europe.

Controversies· Jun 4

The US Supreme Court has ruled unanimously against Amarin Corporation plc ($AMRN) in a patent case, handing a victory to Hikma Pharmaceuticals.
The Supreme Court's decision allows generic versions of Amarin's Vascepa to be approved, potentially impacting $213.6M in revenue generated by the product in 2025.
Amarin's only product, Vascepa, is now vulnerable to competition from generic versions, which could have significant implications for the company's future.

Technical Analysis· Aug 12

The trend for AMRN is strong, with a classic inverted head and shoulders reversal pattern, and the price movement is in a wave pattern that does not matter, only the trend.
The 200-day moving average at 5.35 is a significant indicator, and breaking above this level is a bullish sign, with the stock closing the gap and showing good volume.
The Parabolic Stop and Return (PSAR) indicator has turned positive, supported by the RSI, and the stock is breaking through resistance, with funds able to accumulate shares above 5.

Generated by AI

Community

Of the messages about AMRN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	22.22%	90.28%	91.38%	96.02%
Newcomers	77.78%	9.72%	8.62%	3.98%

Regulars· Sep 5

Novartis's pelacarsen failed to reduce cardiovascular risks in the HORIZON trial, while Amarin's vascepa has shown up to 25-28% CVD risk reduction.
Novartis's Entresto is declining, and its next-gen CV pipeline is still years away, making Amarin's protected next-generation EPA franchise strategically relevant.
Amarin's shareholders are pushing for a buyback, with some suggesting a potential acquisition by Novartis for $2-3 billion, citing the exclusive patents in EU/ROW running up to 2039.

Newcomers· Jun 25

New investors are looking at AMRN's potential for 8-10% annual growth through 2040, valuing the stock at $20/share.
Some newcomers are comparing AMRN's growth to other stocks, such as AAL and WLN.PA, and are optimistic about its prospects.
There is interest in AMRN's valuation and growth potential, with some users noting that the stock is "underpriced".

Generated by AI

News

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.

20d agofinance.yahoo.com

Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026

Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA) 2026 ESC/European Renal Association (ERA) Cardiovascular and Chronic Kidney Disease Guideline Further Reinforces the Clinical Evidence Supporting Icosapent Ethyl DUBLIN and BRIDGEWATER, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascula

29d agoYahoo Finance

Amarin analysis links Vascepa adherence to greater, longer-lasting heart benefits (AMRN:NASDAQ)

1mo agoSeeking Alpha

Amarin to Present New REDUCE-IT and EPA Analyses at ESC Congress 2026

Amarin Corporation plc (NASDAQ:AMRN) will present new REDUCE-IT and EPA analyses at the European Society of Cardiology Congress 2026, adding further research around icosapent ethyl, cardiovascular risk factors and potential mechanisms associated with eicosapentaenoic acid. The presentations, scheduled for August 28 through August 30 during the Munich conference, will examine areas including treatment adherence, longer-term outcomes, lipoprotein(a), coagulation biomarkers and cellular pathways re

1mo agoYahoo Finance

Amarin (AMRN) Q2 2026 Earnings Call Transcript

Detailed price information for Amarin Corp ADR (AMRN-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Amarin (AMRN) Q2 2026 Earnings Call Transcript

Detailed price information for Amarin Corp ADR (AMRN-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about AMRN also mention

#	Name	Attention
1	HZNP - Horizon Therapeutics Public Limited Company	——
2	Matinas BioPharma Holdings, Inc.MTNB	0.02%+0.02
3	Acadia Pharmaceuticals Inc.ACAD	0%+0
4	NAVB - Navidea Biopharmaceuticals, Inc.	——
5	Exelixis Inc.EXEL	0%-0.03
6	Catalyst Pharmaceuticals Inc.CPRX	0%new
7	GSK plc ADRGSK	0%0
8	Sarepta Therapeutics, Inc.SRPT	0%-0.01
9	Arrowhead Pharmaceuticals, Inc.ARWR	0%+0
10	Ironwood Pharmaceuticals, Inc. Class A Common StockIRWD	0%new

Amarin Corporation plc ADR

Healthcare
Drug Manufacturers - General

Amarin Corporation plc ADR is a biopharmaceutical company focused on cardiovascular health. Its commercial activities center on developing and marketing therapies for patients with elevated triglycerides and other cardiovascular risk factors, with Vascepa as its primary marketed product. The company serves healthcare providers and patients across the United States, Europe, and other international markets, using a model built around prescription medicines and physician-driven adoption. Amarin Corporation plc ADR operates in the pharmaceutical sector with an emphasis on lipid science and omega-3-based therapy, positioning its products within the broader treatment landscape for cardiovascular disease management. Headquartered in Dublin, Ireland, the company remains concentrated on commercializing approved therapies and supporting their use in routine clinical care.

Website

Location

One Central Plaza

Dublin, D02 K7K5

Ireland

Social

What share of all stock conversation is about AMRN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% -0.01

Sep 5

Novartis' heart drug, pelacarsen, failed to meet its primary endpoint in a Phase III trial, reducing the risk of cardiovascular events.
Amarin's therapy, icosapent ethyl, has shown hard CV event reduction despite residual risk remaining after standard lipid therapy, and has emerging mechanistic data showing it can limit oxidation of Lp(a) without needing to lower the Lp(a) concentration itself.
Amarin's stock price is undervalued, with a market capitalization of around $2 billion, which is lower than its actual and realistic value, and its shareholders are deserving of some buyback or M&A attention.

Generated by AI

Sentiment

Of the messages about AMRN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% -50	75% +13.89	77.53% +2.09	89.68% +4.93
Bearish	50% new	25% -13.89	22.47% -2.09	10.32% -4.93

Bullish· Feb 25

AMRN has a strong cash position with $300M in cash and no debt, making it a relatively safe value play.
The company's decision to drop a less profitable business to focus on profits has improved its bottom line and is a positive development.
The current share price of $13.71 is undervalued and has the potential to reach $200/share, with some analysts predicting a buyout in the near future.

Bearish· Jun 4

The SCOTUS decision could potentially lead to increased US drug prices as generic drugmakers may be more likely to make and sell their lower-cost drugs.
Amarin's limited product portfolio and lack of a diversified business may make it less valuable and less attractive to potential buyers.
The company's ongoing legal issues, including the remanded court case, may continue to weigh on its stock price and make it harder for Amarin to generate shareholder value.

Generated by AI

Topics

Of the messages about AMRN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	62.5%	87.5%	55.63%
Controversies	0%	0%	3.13%	23.65%
Analysts	0%	0%	0%	3.98%
Macro	0%	37.5%	9.38%	4.22%
Earnings	0%	0%	0%	6.25%
Technical Analysis	0%	0%	0%	6.27%

Earnings· May 3

Amarin Corporation plc ($AMRN) reported Q1 2023 earnings, beating EPS expectations by 167% and revenue expectations by 6%.
The company's gross margin on net product revenue was 55%, down from 76% a year ago, primarily due to a decrease in net selling price.
Amarin's adjusted EPS loss of $0.02 beat the consensus of a loss of $0.03, and revenue of $85.98M beat the consensus of $81.23M.

Analysts· May 12

Goldman Sachs analyst Paul Choi downgraded Amarin Corp from Neutral to Sell, lowering the price target from $6 to $5.
The downgrade was attributed to the company's Q1 results showing revenue decline, and pressure from generics on the ongoing Vascepa launch in the U.S.
Amarin shares dropped 5% after the downgrade, with some analysts expressing skepticism about the validity of the downgrade and suggesting it may be a ploy to get the stock as low as possible for a rebound.

Announcements· Jun 24

Amarin Corporation plc (AMRN) has entered into an exclusive license and supply agreement with Recordati to commercialize VAZKEPA in 59 European countries, providing $25M upfront and up to $150M in sales milestones.
The deal is expected to yield approximately $70M in cost savings over the next 12 months and strengthen Amarin's financial position, potentially making the company cash flow positive.
The partnership allows Amarin to streamline its global operations, reducing costs and increasing the potential for profitability, with Recordati responsible for commercialization of VAZKEPA in Europe.

Controversies· Jun 4

The US Supreme Court has ruled unanimously against Amarin Corporation plc ($AMRN) in a patent case, handing a victory to Hikma Pharmaceuticals.
The Supreme Court's decision allows generic versions of Amarin's Vascepa to be approved, potentially impacting $213.6M in revenue generated by the product in 2025.
Amarin's only product, Vascepa, is now vulnerable to competition from generic versions, which could have significant implications for the company's future.

Technical Analysis· Aug 12

The trend for AMRN is strong, with a classic inverted head and shoulders reversal pattern, and the price movement is in a wave pattern that does not matter, only the trend.
The 200-day moving average at 5.35 is a significant indicator, and breaking above this level is a bullish sign, with the stock closing the gap and showing good volume.
The Parabolic Stop and Return (PSAR) indicator has turned positive, supported by the RSI, and the stock is breaking through resistance, with funds able to accumulate shares above 5.

Generated by AI

Community

Of the messages about AMRN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	22.22%	90.28%	91.38%	96.02%
Newcomers	77.78%	9.72%	8.62%	3.98%

Regulars· Sep 5

Novartis's pelacarsen failed to reduce cardiovascular risks in the HORIZON trial, while Amarin's vascepa has shown up to 25-28% CVD risk reduction.
Novartis's Entresto is declining, and its next-gen CV pipeline is still years away, making Amarin's protected next-generation EPA franchise strategically relevant.
Amarin's shareholders are pushing for a buyback, with some suggesting a potential acquisition by Novartis for $2-3 billion, citing the exclusive patents in EU/ROW running up to 2039.

Newcomers· Jun 25

New investors are looking at AMRN's potential for 8-10% annual growth through 2040, valuing the stock at $20/share.
Some newcomers are comparing AMRN's growth to other stocks, such as AAL and WLN.PA, and are optimistic about its prospects.
There is interest in AMRN's valuation and growth potential, with some users noting that the stock is "underpriced".

Generated by AI

Amarin

Social

Sep 5

Bullish· Feb 25

Bearish· Jun 4

Earnings· May 3

Analysts· May 12

Announcements· Jun 24

Controversies· Jun 4

Technical Analysis· Aug 12

Regulars· Sep 5

Newcomers· Jun 25

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026

Amarin analysis links Vascepa adherence to greater, longer-lasting heart benefits (AMRN:NASDAQ)

Amarin to Present New REDUCE-IT and EPA Analyses at ESC Congress 2026

Amarin (AMRN) Q2 2026 Earnings Call Transcript

Amarin (AMRN) Q2 2026 Earnings Call Transcript

Also Discussed

Amarin Corporation plc ADR

Company Information

Location

Social

Sep 5

Bullish· Feb 25

Bearish· Jun 4

Earnings· May 3

Analysts· May 12

Announcements· Jun 24

Controversies· Jun 4

Technical Analysis· Aug 12

Regulars· Sep 5

Newcomers· Jun 25

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026

Amarin analysis links Vascepa adherence to greater, longer-lasting heart benefits (AMRN:NASDAQ)

Amarin to Present New REDUCE-IT and EPA Analyses at ESC Congress 2026

Amarin (AMRN) Q2 2026 Earnings Call Transcript

Amarin (AMRN) Q2 2026 Earnings Call Transcript

Also Discussed